Boston Scientific Corporation (BSX) Monday said it has agreed to acquire medical technology company Cortex, Inc.
Financial terms of the deal have not been disclosed.
Cortex's OptiMap, a diagnostic mapping solution, helps physicians to identify triggers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder.
"We believe the addition of the Cortex technology complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex AF cases," said Nick Spadea-Anello, global president, Electrophysiology, Boston Scientific.
Boston Scientific expects to complete the transaction in the first half of 2025.
For comments and feedback: editorial@rttnews.com